The Top 4 Longevity Molecules: What Centenarian Science Suggests
Dr Nir Barzilai studies people who reach 100 and finds they do not simply live longer with disease - they stay healthy far longer and are ill only for the last few weeks of life. He explains why he believes the biology of aging itself is the target, and walks through the four-part framework his group uses to score compounds as potentially geroprotective.
Overview
Nir Barzilai founded the Institute for Aging Research at Albert Einstein College of Medicine and has spent decades studying centenarians and their families. His central observation is compression of morbidity: centenarians get the same diseases as everyone else, roughly thirty years later, and are typically sick for only five to eight weeks at the end of life. About a third of those over 100 have no diagnosed disease and take no medication.
He argues this is not disease avoidance but slow aging, and that slow aging is partly heritable - children of centenarians show a biological age about eight years younger, half the cognitive decline, half the cardiovascular disease and half the mortality of their peers. Family studies point to concrete biology, including lipid genes such as CETP and ApoC3 and reduced signalling in the growth hormone and IGF-1 pathway, which illustrates antagonistic pleiotropy: what helps you grow when young can work against you after roughly age 50.
To separate genuine aging-targeted compounds from single-disease drugs, his group uses a twelve-point scale built on four conditions - changing the hallmarks of aging in cells, extending both lifespan and healthspan in already-old animals, preventing several unrelated diseases in human studies, and reducing all-cause rather than disease-specific mortality. Four already-approved compounds score eleven or twelve: metformin, SGLT2 inhibitors, GLP-1 agonists and bisphosphonates such as zoledronic acid.
He is careful about the limits of this knowledge: there is no standard yet for who should take what or when, combinations can overshoot, and every effective compound carries trade-offs - illustrated by a patient who lost fifty pounds and her diabetes but also lost muscle she could not spare. An eight-million-dollar research grant with Dan Belsky now aims to find which markers actually move in response to these interventions.
Key quotes
5They're sick very little time at the end of their life, usually weeks.
It's the biology of aging that drives this disease, and what we're trying to do is interfere with aging before you get the disease.
The four doctors that told me to stop smoking, they died.
The children of centenarians have an eight years younger biological age.
What's the best way that mice can achieve maximal lifespan? The answer is caloric restriction.
Key ideas
9Compression of morbidity is the real goal
Centenarians do not spend forty years being ill. Their sickness compresses into roughly five to eight weeks at the end of life, and around thirty percent of those over 100 carry no diagnosed disease at all.
Same diseases, thirty years later
A German study of people who died at home concluded centenarians are not special because they die of the same causes. Barzilai reads it differently: the diseases are the same, the timing is not, because their aging runs slower.
Why a statin is not a longevity compound
Statins matter for cardiovascular disease but do not extend life in animals or shift the hallmarks of aging. Preventing one disease means arriving at the next one instead, which is why the search is for a shared upstream mechanism.
Genes and environment are an interaction, not a split
Whether the heritable share is twenty percent or fifty percent changes little, because the two work together. Understanding the genetic portion is valuable mainly because it shows where environment could be supported.
Centenarians did not follow the health advice
Compared with NHANES III data, roughly half were overweight, half smoked, half barely moved, and almost none were vegetarian. Their outcome came from something other than exemplary habits.
Exceptional longevity clusters in families
Two centenarian parents are associated with about twenty-four percent more years than local life expectancy, one parent with thirteen percent, and even a third generation shows around seven percent. Offspring also show half the cognitive decline and cardiovascular disease of peers.
Rare lipid gene variants became drug targets
Two genes over-represented in centenarians, CETP and ApoC3, produced favourable cholesterol and triglyceride profiles. Because carriers reached 100, developers treated those pathways as safe to target, and both have since moved through late-stage development.
The growth signal that flips after 50
Around sixty percent of his centenarians carry changes that lower growth hormone and IGF-1 signalling. UK Biobank data suggest higher IGF-1 protects while young and then reverses direction later - the same level that helped now tracks with disease, an example of antagonistic pleiotropy.
A twelve-point scale with four conditions
Two preclinical: shifting the hallmarks of aging in cells, and extending both lifespan and healthspan when given to already-old animals. Two clinical: preventing several unrelated diseases in human trials, and reducing all-cause mortality rather than disease-specific mortality.
Practical takeaways
6- 1
Aim at healthspan, let lifespan follow 5:00
The stated goal is to stay well for as long as possible, with longevity as the side effect - not the other way round.
- 2
Optimise rather than maximise 16:30
Exercise, diet, sleep and social connection all have biological underpinnings, and the word Barzilai uses is optimise: two sessions a week might become three, upper body might be added, without chasing extremes.
- 3
Caloric restriction remains the benchmark 47:00
In mice it produces roughly forty percent longer life, far beyond most compounds. That benchmark is why so much effort has gone into finding something people can realistically sustain instead.
- 4
Repurposing is already routine 50:00
Metformin has been used well beyond diabetes, and each of the four top-scoring compounds turned out to help conditions it was never developed for - which is how their broad effects came to light.
- 5
Watch which markers move, not just a single age score 56:00
A biological age number that never responds to anything is of limited use. The research goal is to know which markers actually shift after three months of a given change.
- 6
Every effective option carries trade-offs 58:20
Muscle falls as body weight falls, and one patient who lost fifty pounds and her diabetes could no longer rise from a chair. Movement and muscle deserve attention alongside any metabolic change - a conversation for a qualified clinician.
Topics & chapters
15Why centenarians matter
The opening frame: people who reach 100 are not just living longer, they are living healthier and dying quickly, with two harmonised cohorts behind the finding.
Do they die of different things?
The German at-home mortality study and what its provocative title actually shows about slowed aging.
Aging as the upstream driver
Why ApoE4 causes nothing at age one or ten, and why a statin - important as it is - is not a longevity drug.
Genetics versus environment
Why the fifty-percent headline changes less than it appears, and how 150 years of environmental change tripled lifespan.
Helen Reiker and the smoking centenarians
Centenarians whose habits contradicted every guideline, including ApoE4 carriers who never developed Alzheimer's.
Is there a ceiling?
A statistical maximum around 115 years, the curve beginning to bend, and why he prefers to focus on the decades most people currently lose.
Centenarian offspring
A fifteen-year longitudinal study of children and their spouses, showing eight years younger biological age and half the age-related burden.
From gene to medicine
CETP and ApoC3, the PCSK9 precedent, and how human genetics de-risked drug development.
IGF-1 and antagonistic pleiotropy
Growth signalling that protects early and harms later, and an antibody that extended both life and health in older animals.
Sirtuin 6 and mRNA delivery
Why resveratrol and sirtuin 1 disappointed, why sirtuin 6 looks different, and how mRNA carriers can reach the liver without altering DNA.
The four conditions and the twelve-point scale
Cells, old animals, multi-disease prevention and all-cause mortality - the full scoring framework for a gerotherapeutic.
Caloric restriction and the search for a mimetic
Forty percent in mice, the impracticality of eating forty percent less, and how GLP-1 agonists arrived at the same problem from another direction.
Metformin and the logic of repurposing
From diabetes prevention to COVID outcomes, PCOS and macular degeneration - and the argument for adding aging to that list.
The four highest scorers, and who decides
Metformin, SGLT2 inhibitors, GLP-1 agonists and bisphosphonates, plus the societies, the Abu Dhabi clinic template and the biomarker grant with Dan Belsky.
GLP-1: origins, breadth and trade-offs
From the Gila monster to weight-independent effects in pair-fed animals, plus the muscle, digestive and tolerance issues that come with them.